Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTR) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T Cell Engagers (TCES), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCES to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTR platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane.
Something looks off?On-site & Remote